Why Luminar Stock Is Rising Today

Luminar Technologies, Inc. (NASDAQ: LAZR) shares are up Tuesday after the company announced a partnership for LiDAR and AI-based assisted driving software for trucking with Plus, a global provider of highly automated driving and fully autonomous

Luminar Technologies, Inc. (NASDAQ:LAZR) shares are up Tuesday after the company announced a partnership for LiDAR and AI-based assisted driving software for trucking with Plus, a global provider of highly automated driving and fully autonomous driving solutions.

What To Know:  Per the agreement, Luminar will offer support to PlusDrive, Plus’s factory-installed assisted driving system for commercial vehicles, by exclusively providing mid- to long-range lidar. In return, Plus will be the exclusive third-party provider of AI-based enhanced driver assist software for Luminar’s solution for commercial vehicle OEMs.

“Trucking is a key emerging market for Luminar, and the same products and technology we’ve successfully executed on for our production consumer vehicle programs are beginning to be deployed on commercial vehicles as well,” said Luminar Founder and CEO Austin Russell. “We see Plus as a new strategic partner for us to enable enhanced safety and autonomous capabilities for production commercial vehicles at even greater scale, in light of their commercial success with some of the largest companies in the industry,” said Russell.

Other areas of collaboration will include Luminar’s commercial vehicle insurance program, high definition mapping, and trucking sensor integration called Blade.

Related Link: Novocure’s Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts

LAZR Price Action: Shares of LAZR were up 6.44% at $7.19 at the time of publication, according to Benzinga Pro.

Image by Davgood Kirshot from Pixabay

 

Total
0
Shares
Related Posts
Read More

GSK Announced Phase IIa Study Results for a New First-in-class Candidate Medicine for Patients With Tuberculosis Showed Early Bactericidal Activity With Low, Once-daily Oral Dose After 14 Days of Treatment in Users With Drug-susceptible Pulmonary TB

GSK plc (LSE/NYSE: GSK) today announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment in participants with drug-susceptible pulmonary tuberculosis.

GSK